Inhibition of tumor growth using Salmonella expressing fas ligand

Journal of the National Cancer Institute

Volumn 100, Issue 15, 2008, Pages 1113-1116

  Loeffler, Markus ^a   Le'Negrate, Gaelle ^a   Krajewska, Maryla ^a   Reed, John C ^a  

^a BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FAS LIGAND; PHOSPHATE BUFFERED SALINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER INHIBITION; COLON CARCINOMA; CONTROLLED STUDY; HOST; IMMUNOCOMPETENCE; INFLAMMATION; LUNG METASTASIS; LUNG WEIGHT; MELANOMA; MOUSE; NONHUMAN; PRIORITY JOURNAL; SALMONELLA TYPHIMURIUM;

ANIMALS; ANTINEOPLASTIC AGENTS; COLONIC NEOPLASMS; FAS LIGAND PROTEIN; FEMALE; GENE EXPRESSION REGULATION, BACTERIAL; INFLAMMATION; INJECTIONS, INTRAVENOUS; MAMMARY NEOPLASMS, EXPERIMENTAL; MELANOMA, EXPERIMENTAL; MICE; SALMONELLA TYPHIMURIUM; TRANSPLANTATION, ISOGENEIC;

EID: 49449116738     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djn205     Document Type: Article

References (22)

1. Thamm DH, Kurzman ID, King I, et al. Systemic administration of an attenuated, tumor-targeting Salmonella typhimurium to dogs with spontaneous neoplasia: phase I evaluation. Clin Cancer Res. 2005;11(13):4827-4834.
2. Rosenberg SA, Spiess PJ, Kleiner DE. Antitumor effects in mice of the intravenous injection of attenuated Salmonella typhimurium. J Immunother. 2002;25(3):218-225.
3. Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis. 2000;181(6):1996-2002.
4. Carrier MJ, Chatfield SN, Dougan G, et al. Expression of human IL-1 beta in Salmonella typhimurium. A model system for the delivery of recombinant therapeutic proteins in vivo. J Immunol. 1992;148(4):1176-1181.
5. Thorburn A. Death receptor-induced cell killing. Cell Signal. 2004;16(2):139-144.
6. Linkermann A, Qian J, Janssen O. Slowly getting a clue on CD95 ligand biology. Biochem Pharmacol. 2003;66(8):1417-1426.
7. Rescigno M, Piguet V, Valzasina B, et al. Fas engagement induces the maturation of dendritic cells (DCs), the release of interleukin (IL)-1beta, and the production of interferon gamma in the absence of IL-12 during DC-T cell cognate interaction: a new role for Fas ligand in inflammatory responses. J Exp Med. 2000;192(11):1661-1668.
8. Ottonello L, Tortolina G, Amelotti M, Dallegri F. Soluble Fas ligand is chemotactic for human neutrophilic polymorphonuclear leukocytes. J Immunol. 1999;162(6):3601-3606.
9. Arai H, Gordon D, Nabel EG, Nabel GJ. Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A. 1997;94(25):13862- 13867.
10. Kidoya H, Umemura M, Kawabe T, et al. Fas ligand induces cell-autonomous IL-23 production in dendritic cells, a mechanism for Fas ligand-induced IL-17 production. J Immunol. 2005;175(12):8024-8031.
11. Suzuki I, Martin S, Boursalian TE, Beers C, Fink PJ. Fas ligand costimulates the in vivo proliferation of CD8+ T cells. J Immunol. 2000;165(10):5537-5543.
12. Ogasawara J, Watanabe-Fukunaga R, Adachi M, et al. Lethal effect of the anti-Fas antibody in mice. Nature. 1993;364:806-809.
13. Rensing-Ehl A, Frei K, Flury R, et al. Local Fas/APO-1 (CD95) ligand-mediated tumor cell killing in vivo. Eur J Immunol. 1995;25(8):2253-2258.
14. Clairmont C, Lee KC, Pike J, et al. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium. J Infect Dis. 2000;181(6):1996-2002.
15. Kayagaki N, Yamaguchi N, Nagao F, et al. Polymorphism of murine Fas ligand that affects the biological activity. Proc Natl Acad Sci U S A. 1997;94(8):3914-3919.
16. Lloyd SA, Sjostrom M, Andersson S, Wolf-Watz H. Molecular characterization of type III secretion signals via analysis of synthetic N-terminal amino acid sequences. Mol Microbiol. 2002;43(1):51-59.
17. Galen JE, Nair J, Wang JY, et al. Optimization of plasmid maintenance in the attenuated live vector vaccine strain Salmonella typhi CVD 908-htrA. Infect Immun. 1999;67(12):6424-6433.
18. Euhus DM, Hudd C, LaRegina MC, Johnson FE. Tumor measurement in the nude mouse. J Surg Oncol. 1986;31(4):229-234.
19. Loeffler M, Le'Negrate G, Krajewska M, Reed JC. Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth. Proc Natl Acad Sci U S A. 2007;104(31):12879-12883.
20. Fleming TJ, Fleming ML, Malek TR. Selective expression of Ly-6G on myeloid lineage cells in mouse bone marrow. RB6-8C5 mAb to granulocyte- differentiation antigen (Gr-1) detects members of the Ly-6 family. J Immunol. 1993;151(5):2399-2408.
21. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA. Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest. 2006;116(7):1955-1962.
22. Toso JF, Gill VJ, Hwu P, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol. 2002;20(1):142-152.